AMPK stands for AMP-activated protein kinase. Its job is to monitor cellular energy balance by reading the ratio of AMP to ATP. When energy is scarce — such as during exercise, caloric restriction, or metabolic stress — AMPK shifts the cell into an energy-conserving, energy-producing mode.

That shift means more glucose uptake, more fatty-acid oxidation, more mitochondrial support, and less energy spent on synthetic programs like lipogenesis. In plain language: AMPK helps the cell survive lean conditions by prioritizing efficiency.

AMPK sits at the intersection of metabolism, exercise, and aging because many health-promoting interventions converge on it. Exercise activates it. Caloric restriction activates it. Some well-known metabolic drugs touch it. Once turned on, AMPK influences downstream programs such as autophagy and mitochondrial biogenesis, which are both central to metabolic resilience.

That is why AMPK often appears in both metabolic and longevity discussions. It is not just a weight-regulation pathway. It is a broader stress-adaptation pathway that tells cells how to respond when energy is limited.

MOTS-C is studied as an AMPK-linked mitochondrial signal. One proposed mechanism is disruption of folate metabolism that leads to AICAR accumulation, which can directly activate AMPK. SLU-PP-32, by contrast, does not primarily target AMPK itself; it engages ERR nuclear receptors to produce an overlapping exercise-like gene-expression profile through a different upstream route.

That distinction matters. Two compounds can both look exercise-like in output while still reaching that result through different signaling hierarchies.